Viatris Inc. VTRS
17.83
0.41
2.35%
as of 25 Sep
- Market cap
- $20.0B
- P/E
- 0.0×
Follow VTRS
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Viatris Inc. (VTRS) Return on equity
Viatris Inc.'s return on equity over the twelve months to 30 June 2026 was −2.75%, up 18.3 percentage points from fiscal 2025 (−21.1%). Over the past ten years it has ranged from −21.1% (fiscal 2025) to 13.0% (fiscal 2015) — the current reading is the lowest in ten years. That is below the Drug Manufacturers Specialty & Generic industry median of −0.40% and above the Healthcare sector median of −32.0%.
Return on equity, annual
Annual
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −21.1% | (17.84) |
| FY2024 | −3.24% | (3.50) |
| FY2023 | 0.26% | (9.74) |
| FY2022 | 10.0% | 15.84 |
| FY2021 | −5.84% | (1.99) |
| FY2020 | −3.85% | (3.99) |
| FY2019 | 0.14% | (2.63) |
| FY2018 | 2.77% | (2.93) |
| FY2017 | 5.70% | 1.10 |
| FY2016 | 4.60% | (8.40) |
Against its own ten years
Low −21.1%
High 13.0%
Ten-year median
0.26%
Current reading's percentile
9
Return on equity against peers
| Company | Return on equity |
|---|---|
| ZTS Zoetis Inc. compare | 64.9% |
| NBIX Neurocrine Biosciences, Inc. compare | 22.1% |
| UTHR United Therapeutics Corporation compare | 19.3% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 9.69% |
| RDY Dr. Reddy's Laboratories Ltd compare | 8.21% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| VTRS Viatris Inc. | −2.75% |
| ELAN Elanco Animal Health Incorporated compare | −2.98% |
| HIMS Hims & Hers Health, Inc. compare | −32.0% |
| Drug Manufacturers Specialty & Generic industry median | −0.40% |
| Healthcare sector median | −32.0% |
| Market median | 1.76% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on VTRS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement